Printer Friendly

DATASCOPE RECEIVES FILING DATE FOR VASOSEAL(TM) PRE-MARKET APPROVAL APPLICATION

 DATASCOPE RECEIVES FILING DATE FOR VASOSEAL(TM) PRE-MARKET
 APPROVAL APPLICATION
 MONTVALE, N.J., April 13 /PRNewswire/ -- Datascope Corp. (NASDAQ: DSCP) announced it has received a "filing letter" today from the Food and Drug Administration (FDA) informing the company that the pre-market approval (PMA) application for its VasoSeal product is suitable for filing. The filing date given is Feb. 3, 1992, the date the PMA was submitted to the FDA.
 Receipt of a filing date represents the first milestone in the PMA approval process following submission of the PMA.
 VasoSeal, announced by the company in April 1991, is the first device that can rapidly seal the arterial puncture created for coronary and peripheral angioplasty, angiography and other procedures requiring arterial catheterizations. The company estimates more than 4.5 million such procedures were performed throughout the world in 1991 including 3.2 million in the U.S.
 -0- 4/13/92
 /CONTACT: Lawrence Saper, chairman of Datascope, 201-307-5508/
 (DSCP) CO: Datascope Corp. ST: New Jersey IN: MTC SU:


SM-OS -- NY080 -- 7924 04/13/92 16:24 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 13, 1992
Words:175
Previous Article:AMERICAN BANK OF CONNECTICUT REPORTS RESULTS
Next Article:SCIENTIFIC-ATLANTA ANNOUNCES SALE OF END-TO-END DIGITAL COMPRESSION SATELLITE ADVERTISING DELIVERY AND INSERTION SYSTEM


Related Articles
DATASCOPE REPORTS 42 PERCENT RISE IN SECOND QUARTER NET
DATASCOPE SUBMITS VASOSEAL PRE-MARKET APPROVAL APPLICATION
DATASCOPE RESPONDS TO FDA REVIEW OF VASOSEAL PMA
DATASCOPE RECEIVES APPROVABLE LETTER FOR VASOSEAL FROM FDA
DATASCOPE RECEIVES APPROVAL OF VASOSEAL FROM FDA
Datascope Reports 1996 Year-End Results; Announces FDA Approval of Early Ambulation Labeling for VasoSeal
Datascope Expects Second Quarter Results Above Wall Street Expectations
Datascope Announces FDA Approval of VasoSeal(R) For Use Following Stent Implantation
Datascope Announces Receipt of CE Mark for VasoSeal(R)
Datascope to Market Second Generation Vasoseal(R) in European Union

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters